Cellular pharmacology of quinone bioreductive alkylating agents

Cancer and Metastasis Reviews

Volumn 12, Issue 2, 1993, Pages 165-176

  Rockwell, Sara ^a   Sartorelli, Alan C ^a   Tomasz, Maria ^b   Kennedy, Katherine A ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

bioreductive alkylating agents, antineoplastic quinones; hypoxia in solid tumors; microenvironmental heterogeneity in solid tumors; mitomycin C; porfiromycin

Indexed keywords

7 N (DIMETHYLAMINOMETHYLENE)MITOMYCIN C; 7 N (DIMETHYLAMINOMETHYLENE)PORFIROMYCIN; BMY 43324; CYTOCHROME B5 REDUCTASE; MITOMYCIN C; MITOMYCIN C DERIVATIVE; PORFIROMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

ANIMAL CELL; CYTOTOXICITY; DNA ADDUCT; DNA CROSS LINKING; DRUG ACTIVATION; DRUG ACTIVITY; DRUG DNA INTERACTION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; HYPOXIA; NONHUMAN; OXIDATION REDUCTION REACTION; OXYGEN CONCENTRATION; PH; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ALKYLATING AGENTS; ANIMAL; CELL HYPOXIA; CELL LINE; CELL SURVIVAL; HUMAN; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; OXYGEN; QUINONES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027327213     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/BF00689808     Document Type: Article

References (62)

1. Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA
2. Metabolism and reactions of quinoid anticancer agents
3. The mode of interaction of mitomycin C with deoxyribonucleic acid and other polynucleotides in vitro
4. Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of a major covalent adduct
5. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA
6. Porfiromycin disposition in oxygen modulated P388 cells
7. Isolation, identification, and assay of [3H]-porfiromycin adducts of EMT6 mouse mammary tumor cell DNA: effects of hypoxia and dicoumarol on adduct patterns
8. Detection and identification of major adducts of3H-mitomycin C and DNA formed in EMT6 mouse mammary tumor cells
9. Role of NADPH-cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C
10. Metabolic activation of mitomycin C by liver microsomes and nuclei
11. Reactive metabolism and alkylating activity of mitomycin C induced by rat liver microsomes
12. Activation of mitomycin C and quinone drug metabolism by NADPH-cytochrome P-450 reductase
13. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase
14. Metabolites and DNA adduct formation from flavoenzyme activated porfiromycin
15. Effects of glutathione and ethylxanthate on mitomycin C activation by isolated rat hepatic or EMT6 mouse mammary tumor nuclei
16. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells
17. Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors
18. Reductive activation of mitomycin C by NADH-cytochrome b5 reductase
19. DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line from mitomycin C and its analogues
20. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones
21. A general mechanism for microsomal activation of quinone anticancer agents to free radicals
22. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics
23. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics
24. H2O2 generation during the redox cycle of mitomycin C and DNA bound mitomycin C
25. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals
26. Evidence for the generation of free hydroxyl radicals from certain quinone antitumor antibiotics upon reductive activation in solution
27. Radiation and hydrogen peroxide induced free radical damage to DNA
28. DNA damage and oxygen radical toxicity
29. DT-diaphorase and chemotherapy
30. Activity of quinone alkylating agents in quinone-resistant cells
31. Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions
32. Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual
33. Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation
34. Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase
35. Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo
36. Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo
37. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells
38. Reductive activation of mitomycin C: a delicate balance
39. Decreased NADPH: cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions
40. Enhancement of mitomycin C cytotoxicity to hypoxic cells by dicoumarol in vivo and in vitro
41. Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro
42. Effect of DT-diaphorase overexpression on mitomycin C toxicity for Chinese hamster ovary cells
43. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro
44. Preclinical studies of porfiromycin as an adjunct to radiotherapy
45. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo
46. Cytotoxicity and DNA cross-links produced by mitomycin analogs in aerobic and hypoxic EMT6 cells
47. Effects of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions
48. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells
49. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant
50. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells
51. Effects of caffeine on Lcells exposed to mitomycin C
52. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro
53. pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells
54. Hypoxic cells as specific drug targets for chemotherapy
55. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells
56. Mechanism of transport and intracellular binding of porfiromycin in HCT 116 human colon carcinoma cells
57. Therapeutic attack of hypoxic cells of solid tumors: presidential address
58. Use of hypoxia-directed drugs in the therapy of solid tumors
59. Mitomycin: ten years after approval for marketing